Cargando…
Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer
Increasing interest in repurposing the diabetic medication metformin for cancer treatment has raised important questions about the translation of promising preclinical findings to therapeutic efficacy, especially in non-diabetic patients. A significant limitation of the findings to date is the use o...
Autores principales: | Litchfield, Lacey M., Mukherjee, Abir, Eckert, Mark A., Johnson, Alyssa, Mills, Kathryn A., Pan, Shawn, Shridhar, Viji, Lengyel, Ernst, Romero, Iris L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695136/ https://www.ncbi.nlm.nih.gov/pubmed/26172303 |
Ejemplares similares
-
Statin Therapy Is Associated with Improved Survival in Patients with Non-Serous-Papillary Epithelial Ovarian Cancer: A Retrospective Cohort Analysis
por: Habis, Mohammed, et al.
Publicado: (2014) -
Metformin is synthetically lethal with glucose withdrawal in cancer cells
por: Khurana, Ashwani, et al.
Publicado: (2012) -
Platinum-Sensitive Recurrence in Ovarian Cancer: The Role of Tumor Microenvironment
por: Chien, Jeremy, et al.
Publicado: (2013) -
The Effects of Chemotherapeutics on the Ovarian Cancer Microenvironment
por: Eckert, Mark A., et al.
Publicado: (2021) -
Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis
por: Ladanyi, Andras, et al.
Publicado: (2018)